At the 2026 Chery International User Summit, Chery introduced a new integrated travel ecosystem combining autonomous Robotaxi, electric vertical takeoff and landing (eVTOL) aircraft, and advanced smart valet parking. This system aims to connect land and air travel seamlessly, reducing travel mode changes and overcoming geographic and traffic challenges. Chery's vision includes automated vehicle management and fast charging technologies to enhance travel efficiency and flexibility. This initiative marks Chery's shift from vehicle development to creating a comprehensive, multi-modal mobility network for easier and more convenient travel.
Chery's new integrated travel ecosystem is the focus here, with Pluang's Consumer Cyclical sector data providing market context. As of Nov 15, 2026 19:11 WIB, out of 134 priced US stocks in this sector, 82 rose and 50 fell. Notable movers include JMIA at USD 5.33 with a -5.33% change and a typical hold time of 29 days, Capri Holdings Ltd (CPRI) at USD 21.46 up 5.30% with a 41-day hold, and Quantumscape Corp (QS) at USD 3.68 down 5.15% with a 39-day hold.
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem combining a Level 4 Robotaxi, eVTOL aircraft models Lingxiao Q212 and J506, and a Super Intelligent Valet Parking system. This integrated approach aims to ov...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, two eVTOL aircraft models, and a Super Intelligent Valet Parking system. This integrated approach aims to reduce modal transfer...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, eVTOL aircraft Lingxiao models, and Super Intelligent Valet Parking (SIVP). This system aims to seamlessly integrate land and a...
Lumentum Holdings reported a strong Q1 with revenue up 136.5% year-over-year to $1.26 billion and adjusted operating margins expanding to 42.3%. The company saw a 228.8% increase in systems revenue and generated over $108 million from optical switchi...
Cocrystal Pharma has completed dosing in its Phase 1b challenge study of CDI-988, an antiviral drug targeting norovirus prevention and treatment, with no serious adverse events reported. Preliminary efficacy results are expected near the end of 2026,...
